Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04401085 Completed - COVID Clinical Trials

COVID-19: Herd Immunity Study in the Czech Republic

SARSCoV2CZPrev
Start date: April 23, 2020
Phase:
Study type: Observational

The aim of the SARS-CoV-2-CZ-Preval study is to quantify the prevalence of individuals with a history of SARS-CoV-2 coronavirus infection in the Czech population, except for those diagnosed with COVID-19 by methods based on direct detection of SARS-CoV- 2, including individuals with a subclinical course of the disease.

NCT ID: NCT04401072 Recruiting - Covid 19 Clinical Trials

Attitude of Egyptian Population Toward COVID 19 in Ramadan

Start date: April 24, 2020
Phase:
Study type: Observational

During the COVID 19 pandemic and after new cases started to appear in Egypt in march 2020 the Egyptian government issued movement restrictions and placed areas into quarantine to reduce the spread of the virus. Egyptian citizens were encouraged to adopt personal protective measures, such as staying at home , increasing personal hygiene and wearing protective face masks. Ramadan is a holy month and a very special event for all the Muslims worldwide including the Egyptian Muslims . the Egyptians have many rituals and traditions special for Ramadan . normally Egyptian people tend to go to family gatherings and go out for iftar and suhoor in Ramadan .the markets also tend to be very crowded and full of people in Ramadan for buying food and other preparations for Ramadan and Eid Al Fitr. This all can lead to crowdingof people in the streets and markets and increases the chance of the spread of the virus and the chance of infection.Public Awareness play a major rule in reducing the spread of COVID 19 so in this study a survey is done to measure the attitude of the Egyptian population toward COVID 19 in Ramadan and to evaluate if the rituals and traditions in the holy month are affecting the spread of COVID 19 in Egypt.

NCT ID: NCT04401033 Completed - COVID Clinical Trials

Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study)

DECORE
Start date: May 11, 2020
Phase:
Study type: Observational [Patient Registry]

The aim of our study to compare the proportion of patients who develop SARS-CoV-2 disease in 3 groups: patients undergoing a abdominal ultrasound examination in a Specialty Center, patients undergoing endoscopic procedure in a third level hospital with CoronaVirus Disease (COVID-19) hospitalization plants and patients who make a telephonic visit (do not go to the hospital) in the digestive system service.

NCT ID: NCT04400929 Completed - COVID Clinical Trials

Using GM-CSF as a Host Directed Therapeutic Against COVID-19

Start date: June 2, 2020
Phase: Phase 2
Study type: Interventional

The coronavirus disease 2019 (COVID-19) has rapidly become a pandemic. COVID-19 poses a mortality risk of 3-7%, rising to 20% in older patients with co-morbidities. Of all infected patients, 15-20% will develop severe respiratory symptoms necessitating hospital admission. Around 5% of patients will require invasive mechanical ventilation, and up to 50% will die. Evidence in severe COVID-19 suggests that these patients experience cytokine storm and progressed rapidly with acute respiratory distress syndrome and eventual multi-organ failure. Early identification and immediate treatment of hyperinflammation is thus recommended to reduce mortality. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) has been shown to be a myelopoietic growth factor that has pleiotropic effects in promoting the differentiation of immature precursors into polymorphonuclear neutrophils, monocytes/ macrophages and dendritic cells, and also in controlling the function of fully mature myeloid cells. It plays an important role in priming monocytes for production of proinflammatory cytokines under TLR and NLR stimulation. It has a broad impact on the processes driving DC differentiation and affects DC effector function at the mature state. Importantly, GM-CSF plays a critical role in host defense and stimulating antiviral immunity. Detailed studies have also shown that GM-CSF is necessary for the maturation of alveolar macrophages from foetal monocytes and the maintenance of these cells in adulthood. The known toxicology, pharmacologic and safety data also support the use of Leukine® in hypoxic respiratory failure and ARDS due to COVID-19. This study aims to recruit patients with evidence of pneumonia and hypoxia who have increased risk for severe disease and need for mechanical ventilation. The overall hypothesis is that GM-CSF has antiviral immunity, can provide the stimulus to restore immune homeostasis in the lung with acute lung injury from COVID-19, and can promote lung repair mechanisms, which would lead to improvement in lung oxygenation parameters.

NCT ID: NCT04400890 Terminated - COVID-19 Clinical Trials

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

Start date: September 13, 2020
Phase: Phase 2
Study type: Interventional

Resveratrol is a plant polyphenol (that is sold commercially as a supplement) that might help fight coronavirus as well as help protect the body from the effects of disease (COVID-19) caused by the infection. In this proof-of-concept pilot study we will compare the effects of resveratrol to placebo to assess the safety of the resveratrol and explore effectiveness.

NCT ID: NCT04400877 Completed - COVID-19 Clinical Trials

Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic

Start date: June 8, 2020
Phase:
Study type: Observational

The purpose of this study is to investigate the prevalence of venous thromboembolism in a regional health care system (Region Östergötland, Sweden) before and during the SARS-COV-2 pandemic. In a retrospective observational study, we will review patient data, diagnostic data and treatment data over a three-month period since the onset of the SARS-COV-2 pandemic. This data will be compared with data from the corresponding time frame during the years 2015 to 2019.

NCT ID: NCT04400838 Active, not recruiting - Coronavirus Clinical Trials

Investigating a Vaccine Against COVID-19

Start date: May 28, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.

NCT ID: NCT04400812 Enrolling by invitation - COVID-19 Clinical Trials

Attitude and Perception Towards COVID-19 Pandemic

Start date: May 19, 2020
Phase:
Study type: Observational

Assess response and attitude of general population living in Sharkia Governerate, Egypt as regard COVID-19 pandemic through arabic questionnaire.

NCT ID: NCT04400799 Terminated - COVID-19 Clinical Trials

Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

Start date: June 15, 2020
Phase: Phase 3
Study type: Interventional

The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces unplanned hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.

NCT ID: NCT04400461 Completed - COVID-19 Clinical Trials

Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation

Start date: May 15, 2020
Phase:
Study type: Observational

Little is known about the physical function outcomes in patients with severe COVID-19 patients who are admitted to Intensive Care Unit (ICU) for invasive mechanical ventilation. The purpose of this study is to evaluate the short-term impact on physical function before hospital discharge in subjects with severe COVID-19 who have survived ICU admission for invasive mechanical ventilation.